When Revolution Medicines' FDA Win Lifts Other Boats: SELLAS Life Sciences Stock Surges
SELLAS stock gains momentum following FDA approval for Revolution Medicines, highlighting SLS009 preclinical pancreatic cancer data.
Read original at benzingaStocks · News reference
Truist Securities Maintains Buy on Revolution Medicines, Raises Price Target to $239
Truist Securities analyst Gregory Renza maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $231 to $239.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 27, 2026, 1:02 PM
- Checked
- Aug 27, 2026, 1:02 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Revolution Medicines Stock Trades Higher Following Landmark FDA Approval for Pancreatic Cancer Drug
Shares of Revolution Medicines are trading higher Thursday morning as a wave of Wall Street firms issued price target increases following the commercial rollout of the company's first-in-class oncology therapy.
Read original at benzingaRevolution Medicines’ Pancreatic Cancer Drug Approval Validates Microcap Propanc Biopharma’s Breakthrough Survival Results
Propanc Biopharma reports strong preclinical data from pancreatic cancer drug, PRP, showing over 90% tumor inhibition and extended survival.
Read original at benzingaOppenheimer Maintains Outperform on Revolution Medicines, Raises Price Target to $260
Oppenheimer analyst Jay Olson maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $230 to $260.
Read original at benzinga